Gregory Schaaf, Ph.D., is an experienced scientist currently serving as the Study Manager in the Core Targeted Services group at Metabolon, Inc., where they leverage expertise in bioanalytical chemistry and method development. Previously, Schaaf held significant roles at GlaxoSmithKline and Seachaid Pharmaceuticals, contributing to the development of the FDA-approved kinase inhibitor Dabrafenib and leading projects in antibiotic research. Schaaf earned a Doctor of Philosophy in Organic Chemistry from the University of Virginia and has pursued further education in Clinical Trials Design and Management at the University of California, San Diego. Their skill set includes liquid chromatography-mass spectrometry, analytical method development, and medicinal chemistry.
This person is not in the org chart
This person is not in any teams
This person is not in any offices